FT : Private equity groups battle it out for $15bn schools group

Private equity groups battle it out for $15bn schools group
Bain Capital, Permira and Veritas Capital among contenders in final round of Nord Anglia auction

Three private equity groups are battling it out in the final stages of an auction process for school operator Nord Anglia, in what is likely to be one of the largest European deals of the year.

Bain Capital, Permira and Veritas Capital are among the contenders through to the last round of the sale process, according to people familiar with the matter.

Final bids for a majority stake in the London-based group are due later this month and the business could be valued at up to $15bn, the people added. Other bidders could yet be involved, one of the people cautioned.

Nord Anglia’s existing owners — Swedish private equity group EQT and the Canada Pension Plan Investment Board — are likely to retain a stake in any deal, the people said. The Singapore wealth fund GIC is also likely to co-invest alongside a possible winning bidder, they added.

The deal is among the largest potential transactions in Europe this year, ranking alongside the likes of Abu Dhabi’s National Oil Company’s potential €14.4bn deal for German chemical group Covestro, and would-be acquirers face complications due to the deal’s multibillion-dollar size.

Larger private equity takeovers have faced challenges in recent years as higher interest rates make financing the deals more costly.

Another consideration is how the new potential owner could generate a return from the deal, given the business is now so large it would likely need to return to the public markets via an initial public offering, one of the people said.

While the European market for new listings has had its strongest start to the year since the Covid-19 pandemic, it still remains choppy.

EQT and CPPIB could still seek an IPO for Nord Anglia as a back-up plan if a sale does not materialise, the people added.

Nord Anglia has 87 international day and boarding schools in 33 countries, including in China, India, the Middle East and Americas. In the past two years alone the company has added 10 schools largely via acquisitions.

Some of its schools include the Oxford International College in the UK and the exclusive Avenues in New York.

In the UK, where Nord Anglia has a small number of schools, the new governing Labour party has previously said it would cut a tax perk for private schools and impose business rates on them.

More than 85,000 students up to the age of 18 are in its schools alongside 11,000 teachers and thousands more support staff.

EQT’s Baring Private Equity Asia and CPPIB acquired Nord Anglia in 2017, delisting the company from the New York Stock Exchange for $4.3bn including debt.

Private equity groups face a double-sided challenge. They are under pressure from their backers to sell off assets in order to return cash, and must also make investments from their new buyout funds in a slower market.

Education has proved a popular sector for investment in the private markets.

A consortium led by the Canadian investment group Brookfield agreed a deal last month to invest in the Dubai-based education company GEMS.

Meanwhile, the French investor Wendel earlier this month took a 50 per cent stake in the European primary and secondary school group Globeducate for €625mn, acquiring part of current shareholder Providence Equity Partners’ interest.

Veritas did not respond to requests for comment. Bain, Permira, GIC, EQT, CPPIB and Nord Anglia declined to comment.

The Information : Crypto Trading Giant Wintermute In Fundraising Talks

Crypto Trading Giant Wintermute In Fundraising Talks

The Takeaway
• Wintermute is Robinhood’s biggest crypto market maker
• Firm filled vacuum after rival market makers shuttered or pulled back
• Wintermute is profitable, expanding in Asia

Wintermute Trading, the crypto trading firm that has become a dominant market marker since the collapse of FTX, has been in talks to raise fresh money in a funding round, according to investors with knowledge of the process.

The firm has been discussing a share sale of $100 million, with some of that money going to existing shareholders. Wintermute will also issue new shares, the people said, although the amount couldn't be learned. The talks are in flux and details are not finalized, the people added.

Wintermute buys and sells crypto on exchanges like Binance, Coinbase and Kraken, ensuring investors can trade quickly, and makes money on the spread. The firm gained market share after some market making rivals were wiped out following FTX’s implosion in 2022, and as big traditional quantitative trading firms including Jump Trading and Jane Street pulled back from crypto trading.

That has put Wintermute in a prime position to benefit as investor interest in trading crypto picked back up. The firm is currently profitable, the people said, though it’s yet to match the peak of its 2021 performance, when it generated $1.05 billion in revenue and $582 million in net profit.

A representative for Wintermute did not immediately have a comment.

One sign of Wintermute’s dominance is its relationship with crypto and stock trading app Robinhood. Market makers like Wintermute and Citadel Securities pay Robinhood in exchange for the app sending them orders to execute. Wintermute was Robinhood’s biggest crypto maker in the first quarter, according to a Robinhood filing, and its payments made up 10% of Robinhood’s $618 million in overall revenue.

Wintermute has also benefited from the launch of bitcoin exchange-traded funds earlier this year. In the U.S., Wintermute is a significant liquidity provider for crypto exchange Coinbase, where many fund issuers buy and sell the bitcoin that the ETFs hold. It also executes bitcoin trading for some ETF issuers in Hong Kong and the U.S. directly, without going through an exchange like Coinbase.

Wintermute CEO Evgeny Gaevoy founded the firm in London in 2017 after a decade-long trading career at Optiver, one of the world’s oldest market-making firms. His wife, Marina Gurevich, was part of the founding team and is the firm’s now chief operating officer. Wintermute’s last disclosed fundraising was a $20 million Series B round in 2021 led by Lightspeed Venture Partners, with participation from investors including Pantera Capital.

Wintermute has been expanding in Asia, opening a Singapore office in 2021 and moving some of its staff, including co-founder Yoann Turpin, there last year. The firm also has a venture arm, which backed more than 100 projects including crypto exchange Crossover Markets and brokerage Hidden Road.

The Information : OpenAI Has Talked to Broadcom About Developing New AI Chip

OpenAI Has Talked to Broadcom About Developing New AI Chip

The Takeaway
• OpenAI has hired former Google chip staffers
• ChatGPT maker is talking to Broadcom about working on chip
• Sam Altman has had talks with TSMC

Last year, as the world’s top artificial intelligence developers were racing to speed up their work using ever-bigger clusters of computers, OpenAI CEO Sam Altman was trying to play a longer game. He decided to start a new company that could develop and produce a new AI chip and help set up chip factories to make them and data centers to house them.

His plan has taken numerous twists and turns since then. But there are signs his effort to build a new chip is taking shape, starting within OpenAI rather than via a separate venture.

The ChatGPT maker has been hiring former members of a Google unit that produces Google’s AI chip, the tensor processing unit, and has sought to develop an AI server chip, according to three people who have been involved in the conversations. OpenAI has been talking to chip designers including Broadcom about working on the chip, according to the people.

The team has discussed how the eventual chip could help the new venture Altman has envisioned, which aims to increase the amount of computing power for AI developers such as OpenAI, said one of the people.

A new server chip that would rival the kind made by Nvidia is a long shot that would take years to come to fruition. And in trying to develop a chip, OpenAI risks upsetting Nvidia, OpenAI’s most important chip supplier.

But it could also provide OpenAI with potential leverage in future pricing negotiations with the company. Nvidia has been generating unprecedented profit margins and sales on its AI-focused graphics processing units because customers such as OpenAI don’t have viable alternatives.

Altman’s efforts reflect OpenAI’s concerns about competition from cash-rich tech companies such as Google and Meta Platforms, which are investing heavily in data centers and specialized servers to develop the best AI. Altman has long said that to beat them and achieve its dream of “superintelligence,” OpenAI will need many times the computing capacity it has today. That type of AI could, say, help humans colonize Mars or develop fusion energy, and it’s a long way from what OpenAI’s conversational AI can currently do.

Developing a new type of chip has only been one part of Altman’s plan. In conversations that started in 2023 and continued this year, Altman spoke to executives at key chip manufacturers and suppliers, such as Taiwan Semiconductor Manufacturing Co., which makes Nvidia’s chips, about whether they could boost their capacity to make more Nvidia chips or Altman’s proposed new AI chip, said a senior TSMC manager.

Altman discussed with TSMC and others whether a possible new venture of his could finance dozens of new chip factories that such manufacturers would operate. Altman has also gotten to know Intel CEO Pat Gelsinger, whose firm runs a chip foundry that aims to compete with TSMC.

But Altman’s factory expansion ambitions struck numerous executives as improbable, because it would require a lot of capital and specialized labor.

Altman was “too aggressive for me to believe,” TSMC CEO CC Wei said in a news conference last month when he was asked about the prospect of new factories.

Substantial Orders

Still, behind the scenes, TSMC executives have told Altman that they were open to expanding chip production if he or OpenAI could commit to a substantial amount of orders for the new chips, according to a senior TSMC manager who was briefed about the conversations.

That type of arrangement would be more manageable for TSMC because it could use existing factories in Taiwan rather than trying to set up dozens of new ones.

Another key part of Altman’s plan involves building new data centers to house the chips. Recently, he told one industry executive that he aimed to set up one or more companies with outside investors to pay for real estate, power, data centers and the specialized AI chip servers that would be housed in them. He said OpenAI would commit to renting those servers, this person said.

Altman has sought approval from the U.S. Commerce Department to work on such projects with foreign governments such as in the Middle East, said one person who was formally briefed on the conversation. The agency has been concerned about foreign involvement in critical U.S. sectors such as AI. (Multiple news outlets previously reported on the conversations.)

Altman hasn’t spoken publicly about the specifics of the data center and chips effort, but he has privately told industry executives he would unveil the effort this year. It isn’t clear whether the venture has been incorporated as a company.

As he tried to sway chip manufacturers last year, Altman’s plan became one of many bones of contention between him and OpenAI’s board of directors, which briefly ousted him last fall.

When he first broached the chip idea with the board last year, he initially said it would be independent from OpenAI, according to two people with knowledge of the pitch. Some board members felt his growing array of side projects, including a separate AI device company, would draw his attention away from OpenAI.

Earlier this year, though, he told colleagues that OpenAI would own a stake in the new venture and that OpenAI’s new board of directors has had a chance to review the idea.

“OpenAI is having ongoing conversations with industry and government stakeholders about increasing access to the infrastructure needed to ensure AI’s benefits are widely accessible,” said Liz Bourgeois, a spokesperson for OpenAI. “This includes working in partnership with the premier chip designers, fabricators and the brick and mortar developers of data centers.”

She didn’t comment on the specifics of this article. Broadcom spokespeople didn’t immediately respond to a request for comment.

Funding data center infrastructure is a well-trod path for private equity firms and other investors, and Altman has been forging relationships with numerous firms that might participate. They include SoftBank, which has also discussed a separate Altman venture to develop a consumer AI-powered device; UAE-based sovereign wealth funds; and large private equity firms.

Several governments including the UAE have said they want to develop AI-focused data centers to boost their economy, keep local data protected from outsiders, and increase their standing in the tech industry.

It isn’t clear whether Altman has received commitments from such investors for the plan. The OpenAI spokesperson said the company is working closely with Microsoft, OpenAI’s exclusive cloud server provider, but did not elaborate, and a Microsoft spokesperson did not immediately comment.

The Wall Street Journal earlier this year reported Altman was in talks with investors to raise funds for a chip venture, noting it could require raising up to $7 trillion. But Altman privately has told people that figure represents the sum total of investments that participants in such a venture would need to make, in everything from real estate and power for data centers to the manufacturing of the chips, over some period of years.

A Challenge to Nvidia?

Then there’s the question of whether and how Altman plans to make a new AI chip. OpenAI’s chip-focused team, led by Richard Ho, who also worked on TPUs at Google, will likely choose an American company, such as Broadcom, to help it develop the proposed new chip, said the people who have been involved in the conversations. Broadcom works with Google on the TPUs it makes and has talked to the OpenAI chip team, these people said.

Taiwanese rivals to Broadcom, such as AIchip Technologies, also pitched this type of service to OpenAI, some of these people said.

The OpenAI team doesn’t appear to have started designing the chip, and it wouldn’t be produced until 2026 at the earliest, one of the people said. The team is considering various chip packaging and memory components to maximize the chip’s performance, this person said.

Altman discussed his chip plans with memory chip makers Samsung and SK Hynix earlier this year, according to two people with knowledge of the conversations. Both make high-bandwidth memory chips, which provide a high-speed connection between the processor and the memory, allowing for faster data transfer and processing as the chips make AI computations.

Such memory chips have been in short supply, posing challenges for Nvidia's chips.

If OpenAI or the new venture proceeds with designs for a new AI chip, it might be viewed as an affront to Nvidia. The chip designer has supplied hundreds of thousands of its graphics processing units to Microsoft so that OpenAI could use them to develop ChatGPT and other products.

For Nvidia, however, a customer moving onto its turf would be a familiar sight. For instance, Microsoft, like Google and other large Nvidia customers, also develops its own AI-specific server chip as it tries to lessen reliance on Nvidia chips. There’s no indication OpenAI wants to use the Microsoft chip, though.

Altman took to X in February to lament about not having enough Nvidia GPUs to power his company’s AI development.

Since then, OpenAI has gotten access to more Nvidia-powered servers from Microsoft. And by the middle of 2025, Oracle and Microsoft will provide OpenAI with one of the most powerful clusters of Nvidia servers in the world, which would cost about $2.5 billion per year to rent.

But that’s hardly enough computing capacity for Altman. Already, Microsoft and OpenAI have discussed a future data center that could cost up to $100 billion and was known within OpenAI as “Stargate.” The prospective size of the facility and its server cluster means it would likely require a breakthrough in energy or else face a shortage of power.

It isn’t clear whether the Stargate discussions have become part of Altman’s separate AI data center talks.

>>> US After Hours After Hours Summary: NFLX +1.1% up slightly on earnings; ISRG

After Hours Summary: NFLX +1.1% up slightly on earnings; ISRG +6.5% also a key earnings mover

After Hours Gainers:

Companies trading higher in after hours in reaction to earnings/guidance: RGP +10.6%, ABL +10.5% (guides Q2 revs; also to acquire Carlisle Mgmt for $200 mln), ISRG +6.5%, AIR +1.9%, NFLX +1.1%, WAL +0.2%

Companies trading higher in after hours in reaction to news: HE +39.3% (among cos agreeing to pay $4+ bln to resolve Maui fire lawsuits, according to Bloomberg), SGRY +8.9% (private equity backer explores potential sale, according to Bloomberg), TXT +2.5% (awarded $312 U.S. Navy contract modification), ALSN +1.4% (forms new partnership with Lingong Heavy Machinery), BLKB +1.3% (increases share buyback authorization to $800 mln), META +0.4% (to suspend use of Gen AI tools in Brazil, according to Reuters), WBD +0.4% (in sympathy with NFLX earnings), LSCC +0.3% (extends small FPGA portfolio with new FPGAs), PARA +0.3% (in sympathy with NFLX earnings), DIS +0.1% (in sympathy with NFLX earnings)

After Hours Losers:

Companies trading lower in after hours in reaction to earnings/guidance: SCHL -11.1%, SIGI -7.3%, OCFC -5%, CRSR -4.8%, GBCI -3.7%, PPG -2.9%, MRTN -1.5%

Companies trading lower in after hours in reaction to news: PLUG -9.6% (commences $200 mln common stock offering), AXTA -1.8% (in sympathy with PPG earnings), SCLX -1% (files for 3.5 mln share offering by selling shareholders), MRAM -1% (CFO to step down, reits guidance)

FT : Novartis warns prostate cancer drug price will remain high

Novartis warns prostate cancer drug price will remain high
Swiss drugmaker says it will only sell medication privately if health systems cannot pay

Novartis will only sell its new prostate cancer drug privately if health systems continue to balk at its high price, according to its finance chief, underlying the challenge of expanding access to innovative but expensive new treatments.

Pluvicto is one of a new generation of so-called “radiopharmaceutical” therapies that can help cancer patients live longer, but are expensive to produce due to complex supply chains. The US list price of the drug is about $42,500 a dose, with a treatment cycle of up to six doses, but it is not offered by some European health systems.

Harry Kirsch, Novartis’s chief financial officer, told the Financial Times that the complexity of the product meant the Swiss drugmaker could not significantly cut its price.

“We have to stick firm on the floor price: this [drug] is not simple to manufacture and supply,” he said. “If the respective country and health system can’t [afford] the price that needs to be achieved by us, we provide it on the private market . . . where there is good uptake.”

“Our ambition is of course to get it reimbursed so this product can be available for every patient eligible, but we also have to protect the value of our investment,” he added.

Sales of the drug rose by 45 per cent in the six months to the end of June to $655mn, Novartis reported on Thursday, with $522mn in the US. However, sales in the second quarter — up 44 per cent — were lower than analysts’ forecasts. Kirsch said Novartis needed to “educate” medical professionals about the benefits of the treatment in order to increase referrals.

Shares were down by 3.6 per cent in early afternoon trading on Thursday.

Pluvicto is a highly targeted form of radiotherapy for advanced prostate cancer that contains a targeting compound that seeks out and binds to cancer cells, with a radioactive component that kills them. Clinical trials show that patients on the drug live longer without deteriorating, when compared with current treatments.

Pluvicto uses lutetium-177, a radioactive isotope that has a short half-life, meaning that it must be used within days of being manufactured at Novartis’s sites in the US, Italy and Spain. As a result, the drug has faced supply constraints, and was placed on a US shortage list last year. Kirsch said the company now had “unconstrained” supply, having opened a new facility in Indiana.

The drug has been approved by the UK’s Medicines and Healthcare products Regulatory Agency and by the European Commission. But not all European countries are providing the treatment.

Germany said this month that the drug would be reimbursed by statutory health insurance funds at a price of more than €150,000 per year. But the UK’s healthcare spending watchdog recommended against providing the drug on the NHS in November. It said it was uncertain of its cost effectiveness compared with current treatments.

Kirsch said the company has led recent developments in precision radiotherapy. However, it faces competition from other pharmaceutical groups that have recently entered the sector.

AstraZeneca recently acquired radiotherapy company Fusion Pharmaceuticals for $2.4bn, while Bristol Myers Squibb and Eli Lilly have also bought biotech companies in the sector in the past year.

Novartis raised its annual profit guidance on Thursday after sales of its heart failure, psoriasis and cancer drugs helped it beat expectations in the first half of the year. Sales rose by 11 per cent at constant exchange rates to $12.5bn, and net income was up 45 per cent to $3.2bn, both ahead of expectations.

The company now expects core operating income of mid-to-high teens, up from about 10 to 13 per cent previously.

Le Figaro : la décote de Kering est bien trop importante, estime le bureau d’étu

Confidentiel Bourse: la décote de Kering est bien trop importante, estime le bureau d’études Alpha Value

CONFIDENTIEL BOURSE - Chaque jeudi, Le Figaro Patrimoine et Bourse relaie des informations confidentielles repérées dans les notes d’analystes pour vous aider dans vos décisions d’investissement.

Selon Alphavalue, Kering aurait mangé son pain noir

Toutes les valeurs du luxe n’ont pas culminé en 2023 puisqu’il faut remonter presque trois ans en arrière pour retrouver le record de Kering, non loin de 800€. Mais depuis fin 2022, l’action dérape «principalement en raison de la perte de vitesse de Gucci, du scandale marketing de Balenciaga, puis de l’affaiblissement du marché du luxe à compter du S2 2023», rappelle le bureau d’études parisien AlphaValue. Bref, les résultats semestriels attendus le 24 juillet dégringoleraient de 40 à 45 %.


Et maintenant? «Pour les biens de luxe, les belles années sont derrière nous», jugent-ils, la tension des taux d’intérêt et «des hausses de prix excessives»affectant désormais la demande d’autant qu’en Chine, une conjoncture morose doublée de difficultés immobilières pèsent sur le sentiment des consommateurs. Et c’est dans ce contexte que le groupe a entrepris de se redresser!«Kering considère le retournement de Gucci comme une course de fond plutôt qu’un sprint, ce qui est sage»: la direction de la marque - et aussi celle du groupe - a été renouvelée, de nouvelles collections ont été présentées, et maintenant «il faut être plus patient avec Gucci».

En attendant, la visibilité est faible, ce qui se répercute sur le titre. «Toutefois, Kering présente une décote sectorielle significative et nous pensons que la transition que traverse Gucci est déjà intégrée dans les cours», ajoute AlphaValue, qui estime pour finir que la maque «Gucci a pris les bonnes inflexions stratégiques pour capter l’appétence des consommateurs dès qu’elle sera de retour».